Description:Merestinib, with the CAS number 1206799-15-6, is a small molecule inhibitor primarily targeting the receptor tyrosine kinases, particularly those involved in cancer signaling pathways. It is classified as a potent inhibitor of the MET (mesenchymal-epithelial transition factor) and other related kinases, which play crucial roles in tumor growth, metastasis, and angiogenesis. Merestinib has been investigated for its potential therapeutic applications in various cancers, including non-small cell lung cancer and other solid tumors characterized by MET dysregulation. The compound exhibits a favorable pharmacokinetic profile, allowing for oral administration, and has shown promise in preclinical and clinical studies. Its mechanism of action involves blocking the phosphorylation of MET, thereby inhibiting downstream signaling pathways that contribute to cancer cell proliferation and survival. As with many targeted therapies, the efficacy of Merestinib may be influenced by the genetic and molecular characteristics of the tumor, making biomarker identification an essential aspect of its clinical application.
N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl2 -oxo3 -pyridinecarboxamide is a small molecule that inhibits the activity of epidermal growth factor …
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.